Servier, an independent international pharmaceutical group, has completed the tender offer to acquire all the issued and outstanding shares of common stock of Day One Biopharmaceuticals Inc., a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier’s leadership in low-grade glioma and expands the group’s position in oncology with the ad...